English

Evoke Pharma Inc

EDGAR

EVOK Quarterly report (10-Q) · filed 2025-11-13

Annual consolidated revenue for 2024: about USD 10.25M, using the latest reported figures. The previous period, 2023, was about USD 5.181M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.28 million USD

2025 Q3 · USD

Exact inputs and evidence

Revenue: 4283979 USD Source

Operating margin

-26.56%

2025 Q3 · %

Exact inputs and evidence

Operating Income: -1137688 USD Source
Revenue: 4283979 USD Source

Operating cash flow

-522 thousand USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -2084485 USD Source
Operating Cash Flow: -1562527 USD Source

Cash and cash equivalents: 11.6 million USD 2025-09-30 Source
Exact value

11600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.72 million shares 2025-09-30 Source
Exact value

1722409 shares

Reported share-count change

92.48% · 828 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

894843 shares · 2024-09-30· Source
1722409 shares · 2025-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

14.4 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Revenue: 10249415 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 6941042 USD · 2024-01-01 – 2024-09-30 Source
Revenue: 3080158 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 3752142 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 4283979 USD · 2025-07-01 – 2025-09-30 Source

Net income

-5.23 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Net income: -5352194 USD · 2024-01-01 – 2024-12-31 Source
Net income: -4159428 USD · 2024-01-01 – 2024-09-30 Source
Net income: -1306178 USD · 2025-01-01 – 2025-03-31 Source
Net income: -1570976 USD · 2025-04-01 – 2025-06-30 Source
Net income: -1156208 USD · 2025-07-01 – 2025-09-30 Source

Operating cash flow

-3.32 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -5458742 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -4218700 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -997509 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -1562527 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -997509 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -2084485 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1562527 USD · 2025-01-01 – 2025-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-11-13.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 11 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
capital expenditure: No compatible figures in this window
Total assets: 5 of 11 periods available· newest 2024-12-31
Total liabilities: 5 of 11 periods available· newest 2024-12-31
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+97.8%

Prior period

USD 5.18 million

2023-01-01 – 2023-12-31
Current period

USD 10.25 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

10249415 − 5180630 = 5068785 USD

5180630 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
10249415 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Evoke Pharma Inc · 2024-12-31 Evoke Pharma Inc (edgar:1403708) Year-over-year change in Revenue: 5068785 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 10249415 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1505662 Filing: 000095017025038712 Input fundies:Revenue: 5180630 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1507188 Filing: 000095017025038712
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2.44 million

Prior period

−USD 7.79 million

2023-01-01 – 2023-12-31
Current period

−USD 5.35 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-5352194 − -7792295 = 2440101 USD

-7792295 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-5352194 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Evoke Pharma Inc · 2024-12-31 Evoke Pharma Inc (edgar:1403708) Year-over-year change in Net income: 2440101 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -5352194 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1703681 Filing: 000095017025038712 Input fundies:NetIncome: -7792295 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1705284 Filing: 000095017025038712
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 473,765

Prior period

−USD 4.98 million

2023-01-01 – 2023-12-31
Current period

−USD 5.46 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-5458742 − -4984977 = -473765 USD

-4984977 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-5458742 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Evoke Pharma Inc · 2024-12-31 Evoke Pharma Inc (edgar:1403708) Year-over-year change in Operating cash flow: -473765 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -5458742 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1747769 Filing: 000095017025038712 Input fundies:OperatingCashFlow: -4984977 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1749392 Filing: 000095017025038712
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 10.25 million 100% of revenue
Operating costs Derived USD 15.45 million 151% of revenue
Operating income −USD 5.2 million −51% of revenue
Tax, interest and other Derived USD 148,057 1.4% of revenue
Net income −USD 5.35 million −52% of revenue

Cash

Operating cash flow −USD 5.46 million −53% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 56,778% of revenue.
2021 Operating loss: operating costs were 604% of revenue.
2022 Operating loss: operating costs were 410% of revenue.
2023 Operating loss: operating costs were 243% of revenue.
2024 Operating loss: operating costs were 151% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	23020	13070369 Derived	-13047349	107322 Derived	-13154671	Unavailable	Source 2020-01-01 – 2020-12-31: 23020 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -13047349 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -13154671 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -6630007 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	1618076	9769723 Derived	-8151647	386305 Derived	-8537952	Unavailable	Source 2021-01-01 – 2021-12-31: 1618076 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -8151647 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -8537952 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -12352944 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	2508645	10294782 Derived	-7786137	-2433943 Derived	-5352194	Unavailable	Source 2022-01-01 – 2022-12-31: 2508645 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -7786137 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -5352194 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -6595987 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	5180630	12611521 Derived	-7430891	361404 Derived	-7792295	Unavailable	Source 2023-01-01 – 2023-12-31: 5180630 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -7430891 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -7792295 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -4984977 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	10249415	15453552 Derived	-5204137	148057 Derived	-5352194	Unavailable	Source 2024-01-01 – 2024-12-31: 10249415 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -5204137 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -5352194 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -5458742 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 10.2M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	23020	Revenue: 23020 Open source
20212021-12-31	Revenue	1618076	Revenue: 1618076 Open source
20222022-12-31	Revenue	2508645	Revenue: 2508645 Open source
20232023-12-31	Revenue	5180630	Revenue: 5180630 Open source
20242024-12-31	Revenue	10249415	Revenue: 10249415 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

97.8% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 23020 Open source
20212021-12-31	Year over year	6,929%	Revenue: 1618076 Open source Revenue: 23020 Open source
20222022-12-31	Year over year	55%	Revenue: 2508645 Open source Revenue: 1618076 Open source
20232023-12-31	Year over year	106.5%	Revenue: 5180630 Open source Revenue: 2508645 Open source
20242024-12-31	Year over year	97.8%	Revenue: 10249415 Open source Revenue: 5180630 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -50.8% 2024

Net margin -52.2% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-56,678.3%	Operating Income: -13047349 Open source Revenue: 23020 Open source
20212021-12-31	Operating margin	-503.8%	Operating Income: -8151647 Open source Revenue: 1618076 Open source
20222022-12-31	Operating margin	-310.4%	Operating Income: -7786137 Open source Revenue: 2508645 Open source
20232023-12-31	Operating margin	-143.4%	Operating Income: -7430891 Open source Revenue: 5180630 Open source
20242024-12-31	Operating margin	-50.8%	Operating Income: -5204137 Open source Revenue: 10249415 Open source
20202020-12-31	Net margin	-57,144.5%	Net Income: -13154671 Open source Revenue: 23020 Open source
20212021-12-31	Net margin	-527.7%	Net Income: -8537952 Open source Revenue: 1618076 Open source
20222022-12-31	Net margin	-213.3%	Net Income: -5352194 Open source Revenue: 2508645 Open source
20232023-12-31	Net margin	-150.4%	Net Income: -7792295 Open source Revenue: 5180630 Open source
20242024-12-31	Net margin	-52.2%	Net Income: -5352194 Open source Revenue: 10249415 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 23020 Open source Operating Cash Flow: -6630007 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 1618076 Open source Operating Cash Flow: -12352944 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 2508645 Open source Operating Cash Flow: -6595987 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 5180630 Open source Operating Cash Flow: -4984977 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 10249415 Open source Operating Cash Flow: -5458742 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -5.5M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-6630007	Operating Cash Flow: -6630007 Open source
20212021-12-31	Operating cash flow	-12352944	Operating Cash Flow: -12352944 Open source
20222022-12-31	Operating cash flow	-6595987	Operating Cash Flow: -6595987 Open source
20232023-12-31	Operating cash flow	-4984977	Operating Cash Flow: -4984977 Open source
20242024-12-31	Operating cash flow	-5458742	Operating Cash Flow: -5458742 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -6630007 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -12352944 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -6595987 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4984977 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -5458742 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

59.8% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	134.1%	Total Liabilities: 12648671 Open source Total Assets: 9434048 Open source
20212021-12-31	Liabilities / assets	66.4%	Total Liabilities: 7018068 Open source Total Assets: 10573162 Open source
20222022-12-31	Liabilities / assets	65.5%	Total Liabilities: 7766839 Open source Total Assets: 11851488 Open source
20232023-12-31	Liabilities / assets	136.5%	Total Liabilities: 9648083 Open source Total Assets: 7068546 Open source
20242024-12-31	Liabilities / assets	59.8%	Total Liabilities: 10480997 Open source Total Assets: 17519007 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.66× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	1.23×	Current Assets: 9280792 Open source Current Liabilities: 7535677 Open source
20212021-12-31	Current assets / current liabilities	7.51×	Current Assets: 10560734 Open source Current Liabilities: 1405773 Open source
20222022-12-31	Current assets / current liabilities	7.08×	Current Assets: 11722414 Open source Current Liabilities: 1654544 Open source
20232023-12-31	Current assets / current liabilities	0.71×	Current Assets: 6826909 Open source Current Liabilities: 9648083 Open source
20242024-12-31	Current assets / current liabilities	1.66×	Current Assets: 17237897 Open source Current Liabilities: 10380039 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 12.12 million Exact value Exact value: -12121463 USD 2015-01-01 – 2015-12-31: -12121463 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2015-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -12121463 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12121463 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459017004426/evok-20161231.xml#100317 Filing: 000156459017004426 The citation records this snapshot. The page link may show a newer release later.	−USD 10.5 million Exact value Exact value: -10495838 USD 2015-01-01 – 2015-12-31: -10495838 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2015-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -10495838 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10495838 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459017004426/evok-20161231.xml#114691 Filing: 000156459017004426 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 10.75 million Exact value Exact value: -10748531 USD 2016-01-01 – 2016-12-31: -10748531 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2016-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -10748531 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10748531 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459018004725/evok-20171231.xml#97249 Filing: 000156459018004725 The citation records this snapshot. The page link may show a newer release later.	−USD 8.71 million Exact value Exact value: -8707742 USD 2016-01-01 – 2016-12-31: -8707742 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2016-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -8707742 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8707742 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459018004725/evok-20171231.xml#113570 Filing: 000156459018004725 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 12.23 million Exact value Exact value: -12229512 USD 2017-01-01 – 2017-12-31: -12229512 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2017-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -12229512 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12229512 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459019006404/evok-20181231.xml#76189 Filing: 000156459019006404 The citation records this snapshot. The page link may show a newer release later.	−USD 8.72 million Exact value Exact value: -8716905 USD 2017-01-01 – 2017-12-31: -8716905 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2017-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -8716905 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8716905 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459019006404/evok-20181231.xml#90108 Filing: 000156459019006404 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 7.57 million Exact value Exact value: -7566080 USD 2018-01-01 – 2018-12-31: -7566080 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2018-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -7566080 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7566080 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459020010254/evok-20191231.xml#87782 Filing: 000156459020010254 The citation records this snapshot. The page link may show a newer release later.	−USD 6.98 million Exact value Exact value: -6978560 USD 2018-01-01 – 2018-12-31: -6978560 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2018-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -6978560 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6978560 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459020010254/evok-20191231.xml#98598 Filing: 000156459020010254 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 7.13 million Exact value Exact value: -7125655 USD 2019-01-01 – 2019-12-31: -7125655 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2019-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -7125655 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7125655 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459021012510/evok-20201231.xml#84412 Filing: 000156459021012510 The citation records this snapshot. The page link may show a newer release later.	−USD 5.76 million Exact value Exact value: -5762093 USD 2019-01-01 – 2019-12-31: -5762093 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2019-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -5762093 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5762093 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459021012510/evok-20201231.xml#102054 Filing: 000156459021012510 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 13.15 million Exact value Exact value: -13154671 USD 2020-01-01 – 2020-12-31: -13154671 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2020-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -13154671 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13154671 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459022009118/evok-10k_20211231.htm#1397622 Filing: 000156459022009118 The citation records this snapshot. The page link may show a newer release later.	−USD 6.63 million Exact value Exact value: -6630007 USD 2020-01-01 – 2020-12-31: -6630007 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2020-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -6630007 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6630007 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000156459022009118/evok-10k_20211231.htm#1447396 Filing: 000156459022009118 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 8.54 million Exact value Exact value: -8537952 USD 2021-01-01 – 2021-12-31: -8537952 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2021-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -8537952 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8537952 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017023008942/evok-20221231.htm#1450437 Filing: 000095017023008942 The citation records this snapshot. The page link may show a newer release later.	−USD 12.35 million Exact value Exact value: -12352944 USD 2021-01-01 – 2021-12-31: -12352944 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2021-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -12352944 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12352944 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017023008942/evok-20221231.htm#1514138 Filing: 000095017023008942 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 5.35 million Exact value Exact value: -5352194 USD 2022-01-01 – 2022-12-31: -5352194 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2022-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -5352194 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5352194 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1543380 Filing: 000095017025038712 The citation records this snapshot. The page link may show a newer release later.	−USD 6.6 million Exact value Exact value: -6595987 USD 2022-01-01 – 2022-12-31: -6595987 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2022-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -6595987 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6595987 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017024059516/evok-20231231.htm#1219164 Filing: 000095017024059516 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 7.79 million Exact value Exact value: -7792295 USD 2023-01-01 – 2023-12-31: -7792295 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2023-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -7792295 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7792295 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1705284 Filing: 000095017025038712 The citation records this snapshot. The page link may show a newer release later.	−USD 4.98 million Exact value Exact value: -4984977 USD 2023-01-01 – 2023-12-31: -4984977 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2023-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -4984977 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4984977 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1749392 Filing: 000095017025038712 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 5.35 million Exact value Exact value: -5352194 USD 2024-01-01 – 2024-12-31: -5352194 USD Inspect Net Income Open source Share or cite Citation for Net Income · Evoke Pharma Inc · 2024-12-31 Evoke Pharma Inc (edgar:1403708) Net Income: -5352194 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5352194 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1703681 Filing: 000095017025038712 The citation records this snapshot. The page link may show a newer release later.	−USD 5.46 million Exact value Exact value: -5458742 USD 2024-01-01 – 2024-12-31: -5458742 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Evoke Pharma Inc · 2024-12-31 Evoke Pharma Inc (edgar:1403708) Operating Cash Flow: -5458742 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:08:24Z Snapshot: 29cfec4a33c584f8a4d1e07b28d52c147ed7a885cd16e153f917758d9b6a714b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1403708/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5458742 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1403708/000095017025038712/evok-20241231.htm#1747769 Filing: 000095017025038712 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

78 filings · 2,449 latest values · 2,449 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001403708, 1403708, EVOK, edgar:1403708

Also known as EVOKE PHARMA, INC., Evoke Pharma Inc, Evoke Pharma, Inc.

Evoke Pharma Inc

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation